CDK4 and glioblastoma: This could be important, since the activation of the c-MET/TrkA-B pathways was described as being involved in therapeutic resistance of glioblastoma to CDK4/6i, and c-MET inhibition with altiratinib in combination with CDK4/6i can be effective in this setting [191].